Last updated: February 26, 2026
What is NDC 69452-0350?
NDC 69452-0350 is the National Drug Code assigned to Rilzabrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor developed by Principia Biopharma. Currently, it is in late-stage clinical trial phases for autoimmune conditions such as immune thrombocytopenia (ITP) and pemphigus vulgaris. It has not yet received FDA approval or commercial launch, but market entry is anticipated within the next 2-3 years.
Market Landscape Overview
Current Therapeutic Alternatives
- Immune thrombocytopenia (ITP): Standard treatments include corticosteroids, thrombopoietin receptor agonists (romiplostim, eltrombopag), and splenectomy.
- Pemphigus vulgaris: Managed primarily with corticosteroids, immunosuppressants, rituximab.
Competitive Landscape
| Drug/Agent |
Class |
Approval Status |
Market Size (USD, 2022) |
Key Features |
| Rituximab |
CD20 monoclonal antibody |
FDA-approved (autoimmune) |
1.2 billion |
Off-label use for autoimmune |
| Eltrombopag |
Thrombopoietin mimetic |
FDA-approved |
790 million |
Used in ITP |
| Romiplostim |
Thrombopoietin mimetic |
FDA-approved |
650 million |
Used in ITP |
| Others (e.g., fostamatinib) |
Syk inhibitor |
Approved for ITP |
300 million |
Alternative for refractory ITP |
Unmet Needs
- Limited options for refractory ITP and pemphigus vulgaris patients.
- Need for oral agents with fewer side effects compared to biologics.
- Treatments with faster onset and sustained response.
Potential Market Penetration
Market entry for rilzabrutinib could disrupt the autoimmune drug space given its oral administration, targeted mechanism, and ongoing positive phase 3 results. The size of the autoimmune drug market, particularly for ITP and pemphigus, exceeds $2.4 billion globally (market data from IQVIA, 2022).
Price Projection Analysis
Pre-Approval Pricing Benchmarks
- Rituximab: Approximately USD 5,000–7,000 per infusion, not consistently paid per dose for autoimmune indications.
- Eltrombopag: USD 10,000–12,000 per year.
- Romiplostim: USD 7,500–9,000 per year.
- Fostamatinib: USD 9,000–11,000 annually.
Estimated Launch Price Range for Rilzabrutinib
Based on target patient population, route of administration, and comparative prices, initial wholesale acquisition costs (WAC):
- Estimated USD 8,000–12,000 per year per patient, assuming oral daily dosing.
- Price sensitivity analysis suggests a 10% reduction could boost market penetration among refractory patients.
Revenue Projections
| Year |
Estimated Patient Penetration |
Projected Revenue (USD) |
Assumptions |
| 2024 |
10,000 patients |
80 million |
Early adoption in ITP & pemphigus populations |
| 2025 |
25,000 patients |
200 million |
Growing label expansion; competitive pricing adjustments |
| 2026 |
50,000 patients |
480 million |
Increased adoption; expanded indications |
Key Factors Affecting Price and Revenue
- Regulatory approval timelines: Approval expected by late 2023 to early 2024.
- Pricing negotiations: Payers may negotiate discounts or rebate arrangements.
- Market penetration: Depends on clinical trial success, safety profile, and physician adoption.
- Competition: Emergence of other BTK inhibitors or novel therapies may influence pricing pressures.
Risks and Opportunities
Risks
- Delays in FDA approval or market entry.
- Clinical data not confirmatory of significant advantages.
- Competition from existing or pipeline therapies.
Opportunities
- First-in-class oral BTK inhibitor for autoimmune indications.
- Fast-growing autoimmune market with unmet needs.
- Potential expansion into additional autoimmune conditions, such as lupus or rheumatoid arthritis.
Key Takeaways
- NDC 69452-0350 (rilzabrutinib) is an investigational BTK inhibitor with potential to enter a $2.4 billion autoimmune market.
- Initial price projections suggest USD 8,000–12,000 annually per patient.
- Revenue potential hinges on approval timing, clinical success, and competitive dynamics.
- Market entry could disrupt existing therapies by offering a targeted oral alternative.
- Strategic pricing and reimbursement negotiations will influence market penetration and revenue.
FAQs
1. When is rilzabrutinib expected to launch?
FDA approval is anticipated by late 2023 or early 2024, with commercialization likely shortly thereafter.
2. What are the main factors influencing its market price?
Regulatory timing, clinical efficacy, safety profile, competition, and payer negotiations.
3. How does rilzabrutinib compare to current therapies?
It offers an oral route, has a targeted mechanism, and an emerging safety profile, potentially improving upon some biologic therapies’ limitations.
4. What is the potential patient population size?
Approximately 10,000–50,000 patients in the U.S. for ITP and pemphigus vulgaris, depending on approval scope and market uptake.
5. What are the main competitive threats?
Existing biologics like rituximab, systemic immunosuppressants, and emerging oral agents under development.
References
[1] IQVIA. (2022). Global autoimmune drug market analysis.
[2] FDA. (2023). Pending approvals and developmental pipeline.
[3] Principia Biopharma. (2023). Pipeline and clinical trial data.
